Sermorelin Side Effects: Trial Data Breakdown (2026)

Self-Reported Community Adverse Events for Adult Use

Note on labeling: the events below come from r/peptides, r/PeptideTherapy, and community forums for adult subcutaneous sermorelin use, typically at doses substantially higher than pediatric trial protocols.

Injection-site reactions

The most consistent community feedback. Mild redness, itching, or a small welt at the subcutaneous injection site, typically lasting under 24 hours. Self-reported community sources describe rotating sites and warming the vial to room temperature as factors that reduce reaction frequency.

Brief facial flushing within 10-20 minutes

Community sources commonly describe brief warmth and visible flush after subcutaneous injection. The pattern aligns with what pediatric IV-administration data documented.

Fluid retention or "puffy" feel

Self-reported community timelines describe mild fluid retention — particularly noticeable in the face and hands — during the first 2-4 weeks at higher adult doses. The pattern is dose-dependent and resolves with dose reduction.

Hand tingling

Community reports cluster around transient hand tingling at higher doses, attributed by community sources to GH-induced fluid retention causing median-nerve compression. This is a documented GH-pharmacology pattern (see tesamorelin side effects for the trial-grade version).

Vivid dreams or sleep changes

Most consistent community feedback for evening administration is vivid dreams or restless sleep in the first week.

Less Commonly Reported Events

These appear sparsely in community data.

Increased appetite — sparse; community sources commonly attribute this to broader GH-axis effects.

Lightheadedness post-injection — sparse, attributed to vasodilatory effects.

Joint achiness — uncommon at typical doses; attributed by community sources to fluid-retention effects on joint capsules.

IGF-1 Monitoring Patterns

Community sources for adult sermorelin use commonly describe IGF-1 monitoring at baseline, 6-8 weeks, and 16-24 weeks of use. Self-reported community sources describe dose reduction when IGF-1 exceeds the lab's upper reference range. The community pattern parallels FDA labeling practice for the related tesamorelin product.

Dose-Response Patterns

The pediatric trial dose was 30 mcg/kg/day subcutaneous. Adult community-reported anti-aging doses cluster around 200-500 mcg per dose, daily for 4-8 weeks, then maintenance. Self-reported community sources describe injection-site reactions and fluid retention scaling with daily dose; serious events remain rare at typical adult-use doses.

Dose-Pause and Discontinuation Patterns

Pediatric trial protocols paused dosing for protocol-defined adverse events. Community sources describe two patterns. Pause-and-resume — short breaks when fluid retention or hand tingling becomes intrusive. Dose-cycling — community sources commonly describe 8-12 week on / 4 week off cycles, citing IGF-1 normalization during off-cycles.

Core Supplies for This Protocol

The three essentials for running any reconstituted injectable: cold storage, accurate syringes, and metabolic tracking.

Cooluli Classic 4L Mini Fridge

Compact thermoelectric mini-fridge with heat/cool toggle. The most-mentioned dedicated peptide-storage fridge in research community sources — fits ~20 vials and runs quietly.

BD Ultra-Fine 31G 0.3cc 5/16" Insulin Syringes (Box of 90)

0.3cc 31G syringes — each gradation marks 1 unit (vs 2 units on 1cc), making sub-50-unit peptide doses accurate. BD Ultra-Fine is the most widely-cited brand in peptide community sources.

CONTOUR NEXT GEN Glucose Meter All-In-One Kit

Ascensia's CONTOUR NEXT GEN — the most clinically-validated home glucose meter. Includes 20 test strips + lancing device. Tracks the blood-sugar response GLP-1 users care about, especially during dose escalation.

As an Amazon Associate, The Peptide Catalog earns from qualifying purchases.